|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/727 | |
| A61K 35/16 | |||
| A61K 38/57 | |||
| A61P 7/02 | |||
| A61P 1/00 | |||
| A61P 11/08 | |||
| A61P 9/06 | |||
| A61P 9/12 |
| (11) | Number of the document | 2707005 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12719993.3 |
| Date of filing the European patent application | 2012-05-14 | |
| (97) | Date of publication of the European application | 2014-03-19 |
| (45) | Date of publication and mention of the grant of the patent | 2017-08-23 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2012/058954 |
| Date | 2012-05-14 |
| (87) | Number | WO 2012/152953 |
| Date | 2012-11-15 |
| (30) | Number | Date | Country code |
| 11165869 | 2011-05-12 | EP | |
| 201161487205 P | 2011-05-17 | US |
| (72) |
SCHULTE, Stefan, DE
KALINA, Uwe, DE
MOSES, Michael, DE
FEUSSNER, Annette, DE
|
| (73) |
CSL Behring GmbH,
Emil-von-Behring-Strasse 76, 35041 Marburg,
DE
|
| (54) | METHODS TO REDUCE ADVERSE EVENTS CAUSED BY PHARMACEUTICAL PREPARATIONS COMPRISING PLASMA DERIVED PROTEINS |
| METHODS TO REDUCE ADVERSE EVENTS CAUSED BY PHARMACEUTICAL PREPARATIONS COMPRISING PLASMA DERIVED PROTEINS |